MedPath

Study of absorption and elimination rate of Esomeprazole 10 mg sachet in comparison with standard sachet of Esomeprazole (Nexium®).

Not Applicable
Conditions
In this study, the disease is not examined. The subject of the study is the bioequivalence study of the Esomeprazole 10 mg of test and reference in healthy volunteers..
Registration Number
IRCT20200407046981N12
Lead Sponsor
???? ???????? ????? ????? ????????
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Male
Target Recruitment
24
Inclusion Criteria

The weight limit for each volunteer is between 60 and 100 kg.
All volunteers must be non-smokers.
They must be healthy in terms of liver, kidney, respiratory system, mental and other general health characteristics that will be assessed.

Exclusion Criteria

Known hypersensitivity or idiosyncratic reaction to Esomeprazole or any ingredients.
Subjects with BP = 90/60 mm/Hg or BP = 140/90 mm/Hg.
Regular smoker who smokes more than ten cigarettes daily.
Taking any medicine during two week before dosing.

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Peak Plasma Concentration (Cmax). Timepoint: At 0 (before dosing), 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 10, 12 and 24 hour after dosing. Method of measurement: High-performance liquid chromatography—mass spectrometry (HPLC-MS).
Secondary Outcome Measures
NameTimeMethod
AUC (Area Under the Concentration-Time Curve). Timepoint: During 2 months after intervention. Method of measurement: Using non-compartmental model of Win-Nonlin Professional software version 3.2.A (Pharsight Corporation, USA) or SPSS.
© Copyright 2025. All Rights Reserved by MedPath